Tag Archives: HTG Molecular Diagnostics

Analysts’ Top Healthcare Picks: HTG Molecular Diagnostics (HTGM), Precigen (PGEN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HTG Molecular Diagnostics (HTGM – Research Report) and Precigen (PGEN – Research Report) with bullish sentiments. HTG Molecular Diagnostics (HTGM) H.C. Wainwright

H.C. Wainwright Keeps a Buy Rating on HTG Molecular Diagnostics (HTGM)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report) today and set a price target of $2.00. The company’s shares closed last Monday at $0.66, close to its 52-week low of $0.56.

HTG Molecular Diagnostics (HTGM) Gets a Buy Rating from Canaccord Genuity

In a report released yesterday, Mark Massaro from Canaccord Genuity maintained a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.10, close to its 52-week low

H.C. Wainwright Remains a Buy on HTG Molecular Diagnostics (HTGM)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report), with a price target of $8. The company’s shares closed yesterday at $1.93, close to its 52-week low

HTG Molecular Diagnostics (HTGM) Receives a Rating Update from a Top Analyst

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report) yesterday and set a price target of $5. The company’s shares closed yesterday at $2.32, close to its 52-week low of $2.03. Massaro

Cantor Fitzgerald Reiterates a Buy Rating on HTG Molecular Diagnostics (HTGM)

In a report released today, Jordan Abrams from Cantor Fitzgerald reiterated a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report), with a price target of $7. The company’s shares opened today at $2.38, close to its 52-week low